Home › Research › Biomarkers
High performance plasma amyloid-β biomarkers for Alzheimer’s disease
Akinori Nakamura, Naoki Kaneko, Victor L. Villemagne, Takashi Kato, James D. Doecke, Vincent Doré, Christopher James Fowler, Qiao‐Xin Li, Ralph Nigel Martins, Christopher Cleon Rowe, Taisuke Tomita, Katsumi Matsuzaki, Kenji Ishii, Kazunari Ishii, Yutaka Arahata, Shinichi Iwamoto, Kengo Ito, Koichi Tanaka, Colin Louis Masters, Katsuhiko Yanagisawa. Nature, 2018-01-31
Topic: Amyloid, tau and blood-test diagnosis
This study demonstrated the measurement of high-performance plasma amyloid-β biomarkers by immunoprecipitation coupled with mass spectrometry to predict individual brain amyloid-β status as determined by amyloid-β-PET imaging. Tested using a discovery data set (Japan, n = 121) and a validation data set (Australia, n = 252), all test biomarkers showed high performance when predicting brain amyloid-β burden. In particular, the composite biomarker showed very high areas under the receiver operating characteristic curves in both data sets (discovery, 96.7%, n = 121 and validation, 94.1%, n = 111) with an accuracy approximately equal to 90% when using PIB-PET as a standard of truth. Furthermore, test biomarkers were correlated with amyloid-β-PET burden and levels of Aβ1-42 in cerebrospinal fluid.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Nakamura, A., Kaneko, N., Villemagne, V. L., Kato, T., Doecke, J. D., Doré, V., et al. (2018). High performance plasma amyloid-β biomarkers for Alzheimer’s disease. Nature. https://doi.org/10.1038/nature25456
Vancouver
Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke JD, Doré V, et al. High performance plasma amyloid-β biomarkers for Alzheimer’s disease. Nature. 2018. doi:10.1038/nature25456. PMID: 29420472.
BibTeX
@article{nakamura2018-29420472,
author = {Nakamura, Akinori and Kaneko, Naoki and Villemagne, Victor L. and Kato, Takashi and Doecke, James D. and Doré, Vincent and Fowler, Christopher James and Li, Qiao‐Xin and Martins, Ralph Nigel and Rowe, Christopher Cleon and Tomita, Taisuke and Matsuzaki, Katsumi and Ishii, Kenji and Ishii, Kazunari and Arahata, Yutaka and Iwamoto, Shinichi and Ito, Kengo and Tanaka, Koichi and Masters, Colin Louis and Yanagisawa, Katsuhiko},
title = {{High performance plasma amyloid-β biomarkers for Alzheimer’s disease}},
journal = {Nature},
year = {2018},
doi = {10.1038/nature25456},
pmid = {29420472},
url = {https://doi.org/10.1038/nature25456}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 20 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- All test biomarkers showed high performance when predicting brain amyloid-β burden.
- In particular, the composite biomarker showed very high areas under the receiver operating characteristic curves (AUCs) in both data sets (discovery, 96.7%, n = 121 and validation, 94.1%, n = 111) with an accuracy approximately equal to 90% when using PIB-PET as a standard of truth.
- Test biomarkers were correlated with amyloid-β-PET burden and levels of Aβ1-42 in cerebrospinal fluid.
- These plasma biomarkers also have cost-benefit and scalability advantages over current techniques, potentially enabling broader clinical access and efficient population screening.
Why it matters
Reports amyloid-β biomarkers for Alzheimer's disease measured in blood plasma, which the title describes as high performance.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
How this study scored 60/100
Published in a top-tier journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on strength of evidence, so that was left out: it earned 57 of the 95 points we could judge it on, which is 60 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 10 / 10 | Tier 1 — top-tier general journal (Nature) |
| Journal's citation record | 4 / 4 | Nature: journal h-index 1,841 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | — / 5 | No evidence rating recorded — left out of this score |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2018 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 7 / 7 | Cited 1,680 times (OpenAlex, 2026-10-10) |
| Citations per year | 5 / 5 | 168.0 citations a year over 10 year(s) since 2018 |
| Impact for its field and year | 6 / 6 | Cited 110.3× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 4 / 4 | Cited 499 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Katsuhiko Yanagisawa: h-index 54 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | The University of Tokyo: institution h-index 1,463 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 13 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 29420472) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 57 / 95 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 57 of the 95 points we could judge it on is 60 out of 100. |
| Total | 60 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers
Also tagged “cerebrospinal”
821 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 821 tagged studies.